00000000cam 2200000zi 4500
0019.959619
003CaOODSP
00520260504161725
006m     o  d f      
007cr cn ||||||||
008260205e202604  onc     o    f000 0 eng d
020 |a9780660982663
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-418/2026E-PDF
24500|aLot Release Program for schedule D (biologic) drugs : |brevised guidance document for implementation.
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cApril 2026.
264 4|c©2026
300 |a1 online resource (ii, 17 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Lignes directrices sur le Programme d'autorisation de mise en circulation des lots de drogues visées à l'annexe D (produits biologiques) : lignes directrices révisées pour la mise en Ĺ“uvre.
500 |a"Pub.: 250442."
520 |a"This document outlines the Lot Release Program for Schedule D (biologic) drugs. It also covers the extent of the review and testing of biologic drugs prior to their release for sale in Canada by the Biologic and Radiopharmaceutical Drugs Directorate (BRDD)"--Introduction, page 1.
650 0|aBiologicals|xGovernment policy|zCanada.
650 0|aBiologicals|xLaw and legislation|zCanada.
650 0|aDrug approval|zCanada.
650 0|aDrugs|xTesting|xGovernment policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLignes directrices sur le Programme d'autorisation de mise en circulation des lots de drogues visées à l'annexe D (produits biologiques) : |w(CaOODSP)9.959620
85640|qPDF|s712 KB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H164-418-2026-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/lot-release-program-schedule-d-drugs.html
986 |a250442